



FOR IMMEDIATE RELEASE

## New Clinical Studies Live on Veeva Vault EDC

*Next-generation cloud application enables study build in as little as 7 weeks*

**BARCELONA, Spain — 21 June 2018 — Veeva Systems** (NYSE:VEEV) today announced that leading pharmaceutical companies and CROs are now using **Veeva Vault EDC** to improve data management in their clinical trials. Vault EDC provides a modern, flexible EDC solution to build studies faster and more effectively run trials. In just over a year since the product's availability, 12 early adopters have initiated studies with Vault EDC, including a top 20 global pharmaceutical company. Multiple studies are already live and using Vault EDC across a wide range of therapeutic areas, including oncology, ophthalmology, medical device, and cardiovascular.

"The ability to effectively manage clinical data is essential as trials become more complex," said Alison Liddy, SVP clinical risk and data management at ICON, who is running a trial on behalf of a customer leveraging Veeva Vault EDC. "Veeva Vault EDC gives us a next-generation EDC to collect patient data easier and with greater flexibility."

Vault EDC is helping clinical data management teams accelerate their study design and start trials in as little as seven weeks. Studies are configured utilizing drag-and-drop tools instead of editing complicated lines of code, dramatically reducing time to build a study database. The advanced architecture and easy-to-use, intuitive interface of Vault EDC also deliver a simplified experience managing study changes without costly migrations or downtime.

"We recognize the critical importance that EDC system set-up, maintenance, and flexibility plays in data collection and decision-making during oncology trials," said Robert Wittig, president at Trevie Research who is managing the **International Myeloma Foundation's ASCENT** (Aggressive Smoldering Cure Evaluating Novel Rx Transplant) trial. "Veeva Vault EDC provides a modern, adaptive EDC cloud application that establishes a new era of innovation in clinical data management."

"Veeva is honored to work with leading life sciences companies to streamline clinical data management and accelerate trial execution," said Richard Young, vice president of Veeva Vault EDC. "We're excited to bring the industry a modern EDC application that enables greater speed and agility in clinical trials."

Vault EDC is part of **Veeva Vault Clinical Suite** that combines EDC, CTMS, eTMF, and study start-up to unify **clinical data management** and **clinical operations** on a single cloud platform. Veeva's suite of unified applications provides teams with global visibility of trial processes and information. Now organizations can easily manage their entire trial portfolio and streamline their end-to-end clinical processes.

In other news today, Veeva announced that **Tufts Center for the Study of Drug Development (CSDD)** will preview its study findings on the root causes for delays and inefficiencies impacting trial timelines as a follow-up to the **2017 eClinical Landscape Study**. Read our **press release** to learn more and join Veeva and Tufts CSDD at the DIA 2018 Annual Meeting on Tuesday, June 26, at 1:10 p.m. in theater #2 of the exhibit hall for more details on the study results and their implications. Richard Young will also share Veeva's vision for the future of clinical data management. Learn more at [veeva.com/DIA2018](http://veeva.com/DIA2018).

Also, join the growing Veeva clinical data management community and learn more about Veeva and its clinical partners at the upcoming **Veeva R&D Summit** in Philadelphia, September 16-18.

### Additional Information

For more on Veeva Vault EDC, visit: [veeva.com/eu/EDC](http://veeva.com/eu/EDC)

Connect with Veeva on LinkedIn: [linkedin.com/company/veeva-systems](https://www.linkedin.com/company/veeva-systems)

Follow @Veeva\_EU on Twitter: [twitter.com/veeva\\_eu](https://twitter.com/veeva_eu)

Like Veeva on Facebook: [facebook.com/veevasystems](https://www.facebook.com/veevasystems)

### **About ICON plc**

ICON plc is a global provider of outsourced drug development and commercialisation solutions and services to pharmaceutical, biotechnology, medical device, and government and public health organisations. The company specializes in the strategic development, management and analysis of programs that support clinical development from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 97 locations in 38 countries and has approximately 13,380 employees. For more information [ICONplc.com](http://ICONplc.com)

### **About Veeva Systems**

Veeva Systems Inc. is a leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva has more than 625 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices in Europe, Asia, and Latin America. For more information, visit [www.veeva.com/eu](http://www.veeva.com/eu).

### **Forward-looking Statements**

This release contains forward-looking statements, including the market demand for and acceptance of Veeva's products and services, the results from use of Veeva's products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva's historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva's expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva's financial results are included under the captions, "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations," in the company's filing on Form 10-Q for the period ended April 30, 2018. This is available on the company's website at [veeva.com](http://veeva.com) under the Investors section and on the SEC's website at [sec.gov](http://sec.gov). Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.

###

### **Contact:**

Sue Glanville / Cate Bonthuys Veeva Systems Inc.  
[sue@catalystcomms.co.uk](mailto:sue@catalystcomms.co.uk) / [cate@catalystcomms.co.uk](mailto:cate@catalystcomms.co.uk)  
+44 (0) 7715 817589 / +44 (0) 7746 546773